Syros Pharmaceuticals, Inc. (SYRS)
OTCMKTS
· Delayed Price · Currency is USD
0.0253
-0.0047 (-15.67%)
Mar 31, 2025, 3:01 PM EST
Syros Pharmaceuticals Employees
Syros Pharmaceuticals had 68 employees as of December 31, 2023. The number of employees decreased by 49 or -41.88% compared to the previous year.
Employees
68
Change (1Y)
-49
Growth (1Y)
-41.88%
Revenue / Employee
$5,676
Profits / Employee
-$1,438,456
Market Cap
804.97K
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| Endo Inc. | 2,931 |
| Elite Pharmaceuticals | 64 |
| Glass House Brands | 413 |
| Northwest Biotherapeutics | 25 |
| CytoDyn | 9 |
| Silence Therapeutics | 116 |
| American Oncology Network | 1,525 |
Syros Pharmaceuticals News
- 4 weeks ago - Syros Announces Voluntary Delisting from Nasdaq and SEC Deregistration - Business Wire
- 4 months ago - Syros Pharmaceuticals Stock Sinks As Pivotal Blood Cancer Trial Flunks, Triggers Loan Default - Benzinga
- 4 months ago - Syros Announces Topline Data from SELECT-MDS-1 Phase 3 Trial of Tamibarotene in Higher-Risk Myelodysplastic Syndrome with RARA Gene Overexpression - Business Wire
- 5 months ago - The Schall Law Firm Invites Investors To Join An Inquiry Into Syros Pharmaceuticals, Inc. For Securities Related Infractions - Accesswire
- 5 months ago - Syros Pharmaceuticals Inc Is Being Investigated For Securities Fraud And Shareholders With Losses Are Encouraged To Contact The Schall Law Firm - Accesswire
- 5 months ago - The Schall Law Firm Urges Investors To Join An Inquiry Into Syros Pharmaceuticals, Inc. For Securities Law Violations - Accesswire
- 5 months ago - Syros Pharmaceuticals, Inc (SYRS) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 5 months ago - Syros Pharmaceuticals Inc Is Being Investigated For Securities Fraud And Affected Shareholders Are Encouraged To Contact The Schall Law Firm - Accesswire